Cell-based immune therapy for cancer – Andreas Lundqvist's Group

Our research focuses to understand mechanisms of immune escape in solid tumors.

Andreas Lundqvist's research group.

Our research

The immune system plays an important role to prevent local growth and dissemination of cancer. Therapies based on activating the immune system can result in beneficial responses in patients with cancer. In order to harness the full potential of the immune system T and NK cells need to colonize tumors as well as to display optimal tumor killing potential. We investigate the ability of T and NK cells to migrate towards tumors, to persist within the tumor microenvironment, and to maintain the ability to and recognize and kill tumor cells. We study how T and NK cells interact with cells within the tumor microenvironment and exploit cellular and molecular mechanisms of tumor-induced immunosuppression to develop improved immunotherapy regimens in patients with cancer.

Publications

Selected publications

Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients.
Tong L, Kremer V, Neo SY, Seitz C, Tobin NP, Seliger B, Harmenberg U, Colón E, Scherman Plogell AH, Liu LL, Lundqvist A
Oncoimmunology 2025 Dec;14(1):2481109

Staff and contact

Group leader

All members of the group

Alumni

  • Erik Wennerberg, The Institute of Cancer Research, London
  • Dhifaf Sarhan, Karolinska Institutet
  • Veronika Kremer, ‎ Bristol Myers Squibb
  • Kristina Witt, Oncopeptides
  • Maria Wolodarski, Karolinska University Hospital
  • Ziqing Chen, Princeton University
  • Shi Yong Neo, Agency for Science, Technology and Research (A*STAR), Singapore
  • Khang Luu, Corning Life Sciences
  • Apple Tay, Invitrocue
  • Le Tong, Shenzhen Institute of Advanced Technology